Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | ARAF | P10398 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25635486 | 0.82 | KMT2A (0.57) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL30871249 | 0.81 | HDAC1 (0.52) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL1558074 | 0.81 | MAPT (0.56) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL6887760 | 0.80 | NAAA (0.48) | BRAFHDAC1ALDH1A1CA12CA1 | |
| SCHEMBL1558756 | 0.80 | BRAF (0.65) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL13958740 | 0.80 | POLB (0.42) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL29779139 | 0.80 | EGFR (0.62) | EGFRALDH1A1CA12CA1CA2 | |
| SCHEMBL9785879 | 0.80 | EGFR (0.62) | EGFRALDH1A1CA12CA1CA2 | |
| SCHEMBL690577 | 0.79 | KEAP1 (0.61) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL140037 | 0.79 | FADS1 (0.59) | BRAFHDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12553889-B2 | Small molecules targeting the intrinsically disordered structural ensemble of α-synuclein protect against diverse α-synuclein mediated dysfunctions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-17 | — | — | US | claimed |
| US-20220155287-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | UNIV CALIFORNIA (US) | 2022-05-19 | — | — | US | claimed |
| EP-3941452-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | The Regents of the University of California (US) | 2022-01-26 | — | — | EP | claimed |
| WO-2020190970-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-24 | — | — | WO | claimed |
| US-12553889-B2 | Small molecules targeting the intrinsically disordered structural ensemble of α-synuclein protect against diverse α-synuclein mediated dysfunctions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-17 | — | — | US | disclosed |
| CN-115697993-B | Pyrimidine compounds as AXL inhibitors | 南京正大天晴制药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-115697993-A | Pyrimidines as AXL inhibitors | 南京正大天晴制药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220155287-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | UNIV CALIFORNIA (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220155287-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | UNIV CALIFORNIA (US) | 2022-05-19 | — | — | US | disclosed |
| EP-3941452-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | The Regents of the University of California (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2021239133-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | 南京正大天晴制药有限公司 | 2021-12-02 | — | — | WO | disclosed |
| WO-2020190970-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-24 | — | — | WO | disclosed |
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| WO-2012170371-A1 | COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| CN-102666540-A | Fused azine derivatives for the treatment of acetylcholine receptor related diseases | MSD OSS BV | 2012-09-12 | — | — | CN | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| WO-2011045258-A1 | CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR | N.V. ORGANON (NL) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220155287-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | SNCA, PARK7, SYNCRIP | BRAF 2890/4885HDAC1 1963/4885HDAC3 2349/4885 |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | CHRNA5, CHRM5, CHRNA7 | BRAF 3172/4885HDAC1 331/4885HDAC3 254/4885 |
| US-12553889-B2 | Small molecules targeting the intrinsically disordered structural ensemble of α-synuclein protect against diverse α-synuclein mediated dysfunctions | SNCA, PARK7, HTT | BRAF 3223/4885HDAC1 4350/4885HDAC3 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.